Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)
November 06, 2023 02:00 ET
|
Ultragenyx Pharmaceutical Inc.
ROMA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), azienda biofarmaceutica focalizzata sullo sviluppo e la commercializzazione di nuove terapie per malattie...
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
November 02, 2023 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
Third quarter 2023 total revenue of $98.1 million, Crysvita® revenue of $74.9 million and Dojolvi® revenue of $16.6 million Reaffirmed 2023 expected total revenue guidance between $425 million to...
Ultragenyx anuncia que Mepsevii® (Vestronidasa alfa) ya está aprobado para su inclusión en el Compendio Nacional de Medicamentos de México para el tratamiento de la Mucopolisacaridosis VII (MPS VII)
November 01, 2023 18:34 ET
|
Ultragenyx Pharmaceutical Inc.
CIUDAD DE MÉXICO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., una compañía biofarmacéutica dedicada al desarrollo y comercialización de terapias novedosas para...
Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update
October 26, 2023 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 23, 2023 16:01 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 20, 2023 16:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
October 18, 2023 21:16 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Proposed Public Offering of Common Stock
October 17, 2023 16:02 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease
October 16, 2023 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
Ultragenyx today will provide updates on its development pipeline and gene therapy portfolio at an Analyst Day in New York City and by webcast.
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
October 14, 2023 16:30 ET
|
Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized fracture rate